CARsgen Presents Data from China Pivotal Phase II Trial of BCMA CAR T Zevor-cel (CT053) at 2022 ASH Annual Meeting ...Middle East

SHANGHAI, Dec. 12, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that at the 2022 American Society of Hematology (the "ASH")...

Hence then, the article about carsgen presents data from china pivotal phase ii trial of bcma car t zevor cel ct053 at 2022 ash annual meeting was published today ( Monday 12/12/2022 - 05:08 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( CARsgen Presents Data from China Pivotal Phase II Trial of BCMA CAR T Zevor-cel (CT053) at 2022 ASH Annual Meeting )

Also on site :

• 7-Eleven, Inc. and Mattel Team Up for a Turbocharged Collab for a Limited-Edition Hot Wheels Collectible Car
• 1977 No. 1 Remake of a '60s Girl-Group Classic Set a Mother-Son Chart Record That Still Stands 49 Years Later
• What Is 'Fun-Flation'? The Sneaky Reason Your Next Vacation Is About to Cost Way More